CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM106202
035-os BibID:(WOS)000906505300001 (Scopus)85145501296 (Pubmed)36605210
Első szerző:Abolhassani, Hassan
Cím:Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021 / Hassan Abolhassani, Tadej Avcin, Nerin Bahceciler, Dmitry Balashov, Zsuzsanna Bata, Mihaela Bataneant, Mikhail Belevtsev, Ewa Bernatowska, Judit Bidlo, Péter Blazsó, Bertrand Boisson, Mikhail Bolkov, Anastasia Bondarenko, Oksana Boyarchuk, Anna Bundschu, Jean-Laurent Casanova, Liudmyla Chernishova, Peter Ciznar, Ildikó Csürke, Melinda Erdős, Henriette Farkas, Daria S. Fomina, Nermeen Galal, Vera Goda, Sukru Nail Guner, Péter Hauser, Natalya I. Ilyina, Teona Iremadze, Sevan Iritsyan, Vlora Ismaili-Jaha, Milos Jesenak, Jadranka Kelecic, Sevgi Keles, Gerhard Kindle, Irina V. Kondratenko, Larysa Kostyuchenko, Elena Kovzel, Gergely Kriván, Georgina Kuli-Lito, Gábor Kumánovics, Natalja Kurjane, Elena A. Latysheva, Tatiana V. Latysheva, István Lázár, Gasper Markelj, Maja Markovic, László Maródi, Vafa Mammadova, Márta Medvecz, Noémi Miltner, Kristina Mironska, Fred Modell, Vicki Modell, Bernadett Mosdósi, Anna A. Mukhina, Marianna Murdjeva, Györgyi Műzes, Umida Nabieva, Gulnara Nasrullayeva, Elissaveta Naumova, Kálmán Nagy, Beáta Onozó, Bubusaira Orozbekova, Malgorzata Pac, Karaman Pagava, Alexander N. Pampura, Srdjan Pasic, Mery Petrosyan, Gordana Petrovic, Lidija Pocek, Andrei P. Prodeus, Ismail Reisli, Krista Ress, Nima Rezaei, Yulia A. Rodina, Alexander G. Rumyantsev, Svetlana Sciuca, Anna Sediva, Margit Serban, Svetlana Sharapova, Anna Shcherbina, Brigitta Sitkaustiene, Irina Snimshchikova, Shqipe Spahiu-Konjusha, Miklós Szolnoky, Gabriella Szűcs, Natasa Toplak, Beáta Tóth, Galina Tsyvkina, Irina Tuzankina, Elena Vlasova, Alla Volokha
Dátum:2022
ISSN:1664-3224
Megjegyzések:The J Project (JP) physician education and clinical research collaboration program was started in 2004 and includes by now 32 countries mostly in Eastern and Central Europe (ECE). Until the end of 2021, 344 inborn errors of immunity (IEI)-focused meetings were organized by the JP to raise awareness and facilitate the diagnosis and treatment of patients with IEI. In this study, meeting profiles and major diagnostic and treatment parameters were studied. JP center leaders reported patients' data from 30 countries representing a total population of 506 567 565. Two countries reported patients from JP centers (Konya, Turkey and Cairo University, Egypt). Diagnostic criteria were based on the 2020 update of classification by the IUIS Expert Committee on IEI. The number of JP meetings increased from 6 per year in 2004 and 2005 to 44 and 63 in 2020 and 2021, respectively. The cumulative number of meetings per country varied from 1 to 59 in various countries reflecting partly but not entirely the population of the respective countries. Altogether, 24,879 patients were reported giving an average prevalence of 4.9. Most of the patients had predominantly antibody deficiency (46,32%) followed by patients with combined immunodeficiencies (14.3%). The percentages of patients with bone marrow failure and phenocopies of IEI were less than 1 each. The number of patients was remarkably higher that those reported to the ESID Registry in 13 countries. Immunoglobulin (IgG) substitution was provided to 7,572 patients (5,693 intravenously) and 1,480 patients received hematopoietic stem cell therapy (HSCT). Searching for basic diagnostic parameters revealed the availability of immunochemistry and flow cytometry in 27 and 28 countries, respectively, and targeted gene sequencing and new generation sequencing was available in 21 and 18 countries. The number of IEI centers and experts in the field were 260 and 690, respectively.We found high correlation between the number of IEI centers and patients treated with intravenous IgG (IVIG) (correlation coefficient, cc, 0,916) and with those who were treated with HSCT (cc, 0,905). Similar correlation was found when the number of experts was compared with those treated with HSCT. However, the number of patients treated with subcutaneous Ig (SCIG) only slightly correlated with the number of experts (cc, 0,489) and no correlation was found between the number of centers and patients on SCIG (cc, 0,174).
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Immunology. - 13 : 13 (2022), p. 1-14. -
További szerzők:Avcin, Tadej Bahceciler, Nerin Balashov, Dmitry Bata Zsuzsanna Bataneant, Michaela Belevtsev, Michael Bernatowska, Ewa Bidló Judit Blazsó Péter Boisson, Bertrand Bolkov, Mikhail Bondarenko, Anastasia Boyarchuk, Oksana Bundschu, Anna Casanova, Jean-Laurent Chernishova, Liudmyla Ciznar, Peter Csürke Ildikó Erdős Melinda (1975-) (infektológus, gyermekimmunológus) Farkas Henriette Fomina, Daria S. Galal, Nermeen Goda Vera Guner, Sukru Nail Hauser Péter Ilyina, Natalya I. Iremadze, Teona Iritsyan, Sevan Ismaili-Jaha, Vlora Jesenak, Milos Kelecic, Jadranka Keles, Sevgi Kindle, Gerhard Kondratenko, Irina V. Kostyuchenko, Larysa Kovzel, Elena Kriván Gergely Kuli-Lito, Georgina Kumánovics Gábor Kurjane, Natalja Latysheva, Elena A. Latysheva, Tatiana V. Lázár István (1986-) (geográfus) Markelj, Gasper Markovic, Maja Maródi László (1949-) (gyermekgyógyász infektológus, immunológus) Mammadova, Vafa Medvecz Márta Miltner Noémi (1990-) (molekuláris biológus) Mironska, Kristina Modell, Fred Modell, Vicki Mosdósi Bernadett Mukhina, Anna A. Murdjeva, Marianna Műzes Györgyi Nabieva, Umida Nasrullayeva, Gulnara Naumova, Elissaveta Nagy Kálmán Ónozó Beáta Orozbekova, Bubusaira Pac, Malgorzata Pagava, Karaman Pampura, Alexander N. Pasic, Srdjan Petrosyan, Mery Petrovic, Gordana Pocek, Lidija Prodeus, Andrei P. Reisli, Ismail Ress, Krista Rezaei, Nima Rodina, Yulia A. Rumyantsev, Alexander G. Sciuca, Svetlana Sediva, Anna Serban, Margit Sharapova, Svetlana Shcherbina, Anna Sitkaustiene, Brigita Snimshchikova, Irina Spahiu-Konjusha, Shqipe Szolnoky Miklós Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Toplak, Nataŝa Lajszné Tóth Beáta (1978-) (molekuláris biológus) Tsyvkina, Galina Tuzankina, Irina Vlasova, Elena Volokha, Alla
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM102474
035-os BibID:(cikkazonosító)907125 (WOS)000884917500001 (Scopus)85133265003
Első szerző:Goda Vera
Cím:Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency / Vera Goda, Gergely Kriván, Andrea Kulcsár, Márton Gönczi, Szabolcs Tasnády, Zsolt Matula, Ginette Nagy, Gabriella Bekő, Máté Horváth, Ferenc Uher, Zoltán Szekanecz, István Vályi-Nagy
Dátum:2022
ISSN:1664-3224
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
common variable immunodeficiency (CVID)
primary immunodeficiency
anti-SARS-CoV-2 antibodies
IFN-g producing T cells
IFN-g ELISpot assay
vaccination
Megjelenés:Frontiers in Immunology. - 13 (2022), p. 1-10. -
További szerzők:Kriván Gergely Kulcsár Andrea Gönczi Márton Tasnády Szabolcs Matula Zsolt Nagy Ginette Bekő Gabriella Horváth Máté Uher Ferenc Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Vályi-Nagy István
Pályázati támogatás:2020-1.1.6-JÖVŐ-2021-00011
Egyéb
EFOP-1.8.0-VEKOP-17-2017-00001
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM102567
035-os BibID:(cikkazonosító)905585 (WoS)000827929000001 (Scopus)85133014637
Első szerző:Kiss Zoltán
Cím:Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study) / Zoltan Kiss, István Wittmann, Lórinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szlávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
Dátum:2022
ISSN:1664-3224
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV2 infection
boobster vaccine
4th vaccine
omicron variant (SARS-Co-V2)
delta variant (B.1.617.2)
vaccine effectiveness
mortalitiy
Megjelenés:Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:Wittmann István Polivka Lőrinc Surján György Surján Orsolya Barcza Zsófia Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Pálosi Mihály Szlávik János Schaff Zsuzsa Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Müller Cecília Kásler Miklós Vokó Zoltán (1968-) (epidemiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM070979
035-os BibID:(cikkazonosító)1487 (WoS)000414849200001 (Scopus)85034080239
Első szerző:Oláh Attila (élettanász)
Cím:Targeting Cannabinoid Signaling in the Immune System : "High"-ly Exciting Questions, Possibilities, and Challenges / Attila Oláh, Zoltán Szekanecz, Tamás Bíró
Dátum:2017
ISSN:1664-3224
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Immunology. - 8 (2017), p. 1-14. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Bíró Tamás (1968-) (élettanász)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM101208
035-os BibID:(cikkazonosító)846248 (WoS)000788361300001 (Scopus)85128359299
Első szerző:Szebeni Gábor János (Szeged)
Cím:Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls : a Single Center Study / Gábor J. Szebeni, Nikolett Gémes, Dániel Honfi, Enikő Szabó, Patrícia Neuperger, József Á. Balog, Lajos I. Nagy, Zoltán Szekanecz, László G. Puskás, Gergely Toldi, Attila Balog
Dátum:2022
ISSN:1664-3224
Megjegyzések:Background: Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARSCoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited. Methods: A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety. Results: Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive antiRBD antibody response for healthy controls versus patients after 4 months post Frontiers in Immunology | www.frontiersin.org 1 March 2022 | Volume 13 | Article 846248 Edited by: Laura Maggi, Università degli Studi di Firenze, Italy Reviewed by: Javier Carbone, Gregorio Maraño? n Hospital, Spain Ferenc Uher, Central Hospital of Southern Pest, Hungary *Correspondence: Ga? bor J. Szebeni szebeni.gabor@brc.hu Attila Balog balog.attila@med.u-szeged.hu ? These authors have contributed equally to this work and share first authorship ? These authors share senior authorship Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology Received: 30 December 2021 Accepted: 04 March 2022 Published: 31 March 2022 Citation: Szebeni GJ, Ge? mes N, Honfi D, Szabo? E, Neuperger P, Balog JA?, Nagy LI, Szekanecz Z, Puska? s LG, Toldi G and Balog A (2022) Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Front. Immunol. 13:846248. doi: 10.3389/fimmu.2022.846248 ORIGINAL RESEARCH published: 31 March 2022 doi: 10.3389/fimmu.2022.846248 vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-a producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine. Conclusion: All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
SARS-CoV-2 vaccination
rheumatic and musculoskeletal diseases
anti-RBD neutralizing antibodies
CD4+ T-cell response
CD8+ T-cell response
Megjelenés:Frontiers in Immunology. - 13 (2022), p. 1-11. -
További szerzők:Gémes Nikolett Honfi Dániel Szabó Enikő Neuperger Patrícia Balog József A. Nagy Lajos István (Szeged) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Puskás László G. Toldi Gergely Balog Attila
Pályázati támogatás:2020-1.1.6-JÖVŐ-2021-
NKFIH
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM115831
035-os BibID:(WoS)001102841600001 (Scopus)85177039433
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals / Szekanecz Zoltán, Vokó Zoltán, Surján Orsolya, Rákóczi Éva, Szamosi Szilvia, Szűcs Gabriella, Szekanecz Éva, Müller Cecília, Kiss Zoltán
Dátum:2023
ISSN:1664-3224
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
BNT162b2 vaccine
immunocompromised individuals
Megjelenés:Frontiers in Immunology. - 14 (2023), p. 1-8. -
További szerzők:Vokó Zoltán (1968-) (epidemiológus) Surján Orsolya Rákóczi Éva (1962-) (klinikai szakorvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Éva (1968-) (onkológus szakorvos) Müller Cecília Kiss Zoltán (Pécs)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM103047
035-os BibID:(cikkazonosító)919408 (WoS)000836947300001 (Scopus)85135452371
Első szerző:Vokó Zoltán (epidemiológus)
Cím:Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study) / Zoltán Vokó, Zoltán Kiss, György Surján, Orsolya Surján, Zsófia Barcza, István Wittmann, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Lőrinc Polivka, Mihály Pálosi, János Szlávik, György Rokszin, Cecília Müller, Zoltán Szekanecz, Miklós Kásler
Dátum:2022
ISSN:1664-3224
Megjegyzések:Background: In late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered for the vulnerable population starting from August 2021. Methods: The nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations in the prevention of SARS-CoV-2 infection, Covid-19 related hospitalization and mortality during the Delta wave, compared to an unvaccinated control population without prior SARS-CoV-2 infection. Results: The study population included 8,087,988 individuals who were 18?100 years old at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14?120 days after primary immunization in the 16?64 and 65?100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65?100 years, we found high, 88.1%?92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%?95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%?75.3% and 72.9%?100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14?120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed a moderate decline over time, while booster vaccine types restored effectiveness up to almost 100%, except for the Sinopharm booster. Conclusions: The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines, and this is the first study to provide clear and comparable effectiveness results for six different vaccine types after primary immunization against severe during the Delta pandemic wave.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
booster vaccine
delta variant
vaccine effectiveness
sinopharm
sputnik-V
janssen
Covid-19
Megjelenés:Frontiers in Immunology. - 13 (2022), p. 1-9. -
További szerzők:Kiss Zoltán Surján György Surján Orsolya Barcza Zsófia Wittmann István Molnár Gergő Attila Nagy Dávid Müller Veronika Bogos Krisztina Nagy Péter (1976-) (vegyész) Kenessey István Wéber András Polivka Lőrinc Pálosi Mihály Szlávik János Rokszin György Müller Cecília Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kásler Miklós
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM119169
Első szerző:Zimmerman, Daniel H.
Cím:Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines / Daniel H. Zimmerman, Zoltan Szekanecz, Adrienn Markovics, Kenneth S. Rosenthal, Roy E. Carambula, Katalin Mikecz
Dátum:2024
ISSN:1664-3224
Megjegyzések:Rheumatoid arthritis (RA) is recognized as an autoimmune joint disease driven by T cell responses to self (or modified self or microbial mimic) antigens that trigger and aggravate the inflammatory condition. Newer treatments of RA employ monoclonal antibodies or recombinant receptors against cytokines or immune cell receptors as well as small-molecule Janus kinase (JAK) inhibitors to systemically ablate the cytokine or cellular responses that fuel inflammation. Unlike these treatments, a therapeutic vaccine, such as CEL-4000, helps balance adaptive immune homeostasis by promoting antigen-specific regulatory rather than inflammatory responses, and hence modulates the immunopathological course of RA. In this review, we discuss the current and proposed therapeutic products for RA, with an emphasis on antigen-specific therapeutic vaccine approaches to the treatment of the disease. As an example, we describe published results of the beneficial effects of CEL-4000 vaccine on animal models of RA. We also make a recommendation for the design of appropriate clinical studies for these newest therapeutic approaches, using the CEL-4000 vaccine as an example. Unlike vaccines that create or boost a new immune response, the clinical success of an immunomodulatory therapeutic vaccine for RA lies in its ability to redirect autoreactive pro-inflammatory memory T cells towards rebalancing the "runaway" immune/inflammatory responses that characterize the disease. Human trials of such a therapy will require alternative approaches in clinical trial design and implementation for determining safety, toxicity, and efficacy. These approaches include adaptive design (such as the Bayesian optimal design (BOIN), currently employed in oncological clinical studies), and the use of disease-related biomarkers as indicators of treatment success.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Frontiers in Immunology. - 15 (2024), p. 1-13. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Markovics Adrienn Rosenthal, Kenneth S. Carambula, Roy E. Mikecz Katalin
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.